Lv4
580 积分 2024-04-30 加入
A global view of hepatocellular carcinoma: trends, risk, prevention and management
1个月前
已完结
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors
3个月前
已完结
Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: An open-label, single-arm, phase II clinical trial
4个月前
已完结
The Efficacy and Safetyof Apatinib Plus Camrelizumabin Patients With PreviouslyTreated AdvancedBiliary Tract Cancer: A Prospective Clinical Study
4个月前
已关闭
Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study
4个月前
已完结
Bifunctional anti‑PD‑L1/TGF‑βRII agent SHR‑1701 in advanced solid tumors: a dose‑escalation, dose‑expansion, and clinical‑expansion phase 1 trial
4个月前
已完结
胚胎性r波
5个月前
已完结
[The 2023 Chinese menopause symptom management and menopausal hormone therapy guidelines]
5个月前
已完结
中国绝经管理与绝经激素治疗指南2023版
5个月前
已关闭
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
5个月前
已完结
皖公网安备34019202002308
